Jason A Konner MD (He/Him)
Gynecologic Cancer
Clinical Member, Memorial Sloan Kettering
480 Red Hill RoadMiddletown, NJ 07748
Fax+1 646-888-4265
Overview of Dr. Konner
Dr. Jason Konner specializes in Oncology, with a subspecialty in Gynecologic Cancer. He is currently based in New York and serves as a professor at Early Drug Development. Dr. Konner completed his fellowship in Hematology and Medical Oncology at the Memorial Sloan Kettering Cancer Center, after a residency in Internal Medicine at the Icahn School of Medicine at Mount Sinai/Mount Sinai Hospital. He attended Stanford University School of Medicine and earned his undergraduate degree from Yale College. Dr. Konner's experience lies in hereditary breast/ovarian cancer and gynecologic cancer. He has a number of significant publications and has participated in several clinical trials, primarily focused on different types of cancer.
Education & Training
Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2001 - 2004
Icahn School of Medicine at Mount Sinai/Mount Sinai HospitalResidency, Internal Medicine, 1999 - 2001
Stanford University School of MedicineClass of 1999
Yale CollegeBS, 1990 - 1994
Certifications & Licensure
FL State Medical License 2023 - Present
NJ State Medical License 2016 - 2025
NY State Medical License 2000 - 2025
American Board of Internal Medicine Medical Oncology
Clinical Trials
- Safety, Tolerability and Pharmacokinetics of MORAb-003 in Subjects With Advanced Ovarian Cancer Start of enrollment: 2005 Jun 01
- Intravenous and Intraperitoneal Paclitaxel, Intraperitoneal Cisplatin, and Intravenous Bevacizumab for the Initial Treatment of Optimal Stage II or III Ovarian, Primary Peritoneal, and Fallopian Tube Cancer Start of enrollment: 2006 Aug 01
- Zoptarelin Doxorubicin (AEZS 108) as Second Line Therapy for Endometrial Cancer Start of enrollment: 2013 Apr 01
- Join now to see all
Publications & Presentations
PubMed
- 4 citationsA Phase II Study of Fulvestrant plus Abemaciclib in Hormone Receptor-Positive Advanced or Recurrent Endometrial Cancer.Angela K Green, Qin Zhou, Alexia Iasonos, William A Zammarrelli 3rd, Britta Weigelt
Clinical Cancer Research. 2025-06-03 - Patient outcomes in advanced ovarian cancer treated with an anti-FOLR1 antibody-drug conjugate.Paul Johannet, Matthew Flint, M Herman Chui, Jason Konner, Claire Friedman
Gynecologic Oncology. 2025-04-01 - 1 citationsHistology-Specific Clinical Trial of Lenvatinib and Pembrolizumab in Patients with Sarcoma.Sujana Movva, Kenneth Seier, Viswatej Avutu, Lauren B Banks, Jason Chan
Clinical Cancer Research. 2024-12-16
Journal Articles
- A Phase 1 Dose-Escalation Study of Intraperitoneal Cisplatin, intravenous/intraperitoneal Paclitaxel, Bevacizumab, and Olaparib for Newly Diagnosed Ovarian CancerKaren A Cadoo, Roisin E O'Cearbhaill, Dmitriy Zamarin, Paul J Sabbatini, William P Tew, Carol Aghajanian, Jason A Konner, Gynecologic Oncology
Press Mentions
5 Warning Signs of Ovarian Cancer Every Woman Should KnowJune 23rd, 2022- I Promised My Sister I Would Write About How She Chose to DieJanuary 4th, 2024
Insurance Accepted
- Aetna Choice POS II
Aetna HMO
AvMed Health Open Access
BCBS Blue Card PPO
BCBS Florida BlueCare HMO
BCBS Florida NetworkBlue
BCBS Florida Preferred Patient Care PPO
CIGNA HMO
CIGNA Open Access
CIGNA PPO
Coventry Florida - Employer Group PPO
Empire BCBS HMO
Empire BCBS PPOFirst Health PPO
Great West PPO
Humana ChoiceCare Network PPO
Multiplan PHCS PPO
Multiplan PPO
MVP Healthcare PPO
Oxford Health Freedom
Oxford Health Liberty
QualCare HMO
QualCare PPO
United Healthcare - Direct Choice Plus POS
United Healthcare - Direct Options PPO - Please verify your coverage with the provider's office directly when scheduling an appointment
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
